Fast insight into nanotechnology

Access easily searchable nanoscience data, synthesis methods and literature

dual-drug PLA-TPGS nanoparticles

Based on

1 Articles
2014 Most recent source

Composition

Image only illustrates the order and placement of components as described in literature.

1

poly(lactide)-D-α-tocopheryl polyethylene glycol 1000 succinate

PLA-TPGS
Type Polymer
Formula
Role raw materials
2

docetaxel/tamoxifen mixture

DCL/TAM mixture
Type Complex Compound
Formula
Role loaded material

Properties

General physical and chemical properties

Property Value Source
drug release dependent on drugs

0 more entry available to subscribers only.

Or, view sample content

Applications

Area Application Source
medicine/veterinary

0 more entry available to subscribers only.

Or, view sample content

Characterization

Method Source
dynamic light scattering

0 more entry available to subscribers only.

Or, view sample content

Biological effects

Biological system Test details Source
breast cancer MCF7 cells

0 more entry available to subscribers only.

Or, view sample content

Preparation

Method 1

Type: Physical formation
Source:
Starting materials
  • 1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-{(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}
  • poly(lactide)-D-α-tocopheryl polyethylene glycol 1000 succinate
  • 2-{4-[(1Z)-1,2-diphenylpent-1-en-1-yl]phenoxy}ethyl)dimethylamine
  1. K4J54I9oWP26lphE06EPR
Product

dual-drug PLA-TPGS nanoparticles

Method 2

Type: Physical formation
Source:
Starting materials
  • 1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-{(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}
  • poly(lactide)-D-α-tocopheryl polyethylene glycol 1000 succinate
  • 2-{4-[(1Z)-1,2-diphenylpent-1-en-1-yl]phenoxy}ethyl)dimethylamine
  1. eEbOReRXOuDH3jCQTv0Gg
Product

dual-drug PLA-TPGS nanoparticles

Method 3

Type: Physical formation
Source:
Starting materials
  • poly(lactide)-D-α-tocopheryl polyethylene glycol 1000 succinate
  • 1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-{(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}
  • 2-{4-[(1Z)-1,2-diphenylpent-1-en-1-yl]phenoxy}ethyl)dimethylamine
  1. IUtjrhKPkBuFXRM5Ni8ji
Product

dual-drug PLA-TPGS nanoparticles

Method 4

Type: Physical formation
Source:
Starting materials
  • 1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-{(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}
  • poly(lactide)-D-α-tocopheryl polyethylene glycol 1000 succinate
  • 2-{4-[(1Z)-1,2-diphenylpent-1-en-1-yl]phenoxy}ethyl)dimethylamine
  1. D8sQ2kQ8A8T1IaJnc6WNZ
Product

dual-drug PLA-TPGS nanoparticles

Method 5

Type: Physical formation
Source:
Starting materials
  • 1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-{(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}
  • poly(lactide)-D-α-tocopheryl polyethylene glycol 1000 succinate
  • 2-{4-[(1Z)-1,2-diphenylpent-1-en-1-yl]phenoxy}ethyl)dimethylamine
  1. m7SuzwTiTv1LV8MWRI1u2
Product

dual-drug PLA-TPGS nanoparticles

References

Full content is available to subscribers only

To view content please choose from the following:

We use cookies to improve your experience with our site. More information

Sign up for a free trial